$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
$CRDL Completed a $16 Million Private Placement and Closed a Financing for Gross Proceeds of $14.85 Million, Providing Cash Into Q4 2027.
* Late-Stage Life Sciences Company Focused on Advancing Development of Anti-Inflammatory and Anti-Fibrotic Therapies for Heart Disease.
* CardiolRx™, Modulates Inflammasome Activation, an Intracellular Process driving